Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants
Terminated
Dey LP
Phase 4
2005-01-01
Approval of surfactant by the FDA in 1989 for the treatment of Respiratory Distress Syndrome
(RDS) in premature infants greatly improved survival rates. Newer surfactants approved by the
FDA were more concentrated and had a more rapid onset of action. The overall efficacy of
newer surfactants appeared similar until in 2004, Ramanathan and colleagues suggested that a
double dose of Curosurf improved survival in infants 25-32 weeks gestational age, compared to
infants treated with Survanta, the most commonly used surfactant preparation in the United
States. While the data was suggestive, it was not clear that the improvement in survival was
reproducible or that Curosurf was responsible for the improved survival rates.
The purpose of this study was to investigate the role of Curosurf in improving lung function
and survival rates and reducing the complications of prematurity in very premature infants <
30 weeks gestational age at birth.
Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants
Terminated
Alan Fujii
Phase 4
2005-01-01
Approval of surfactant by the FDA in 1989 for the treatment of Respiratory Distress Syndrome
(RDS) in premature infants greatly improved survival rates. Newer surfactants approved by the
FDA were more concentrated and had a more rapid onset of action. The overall efficacy of
newer surfactants appeared similar until in 2004, Ramanathan and colleagues suggested that a
double dose of Curosurf improved survival in infants 25-32 weeks gestational age, compared to
infants treated with Survanta, the most commonly used surfactant preparation in the United
States. While the data was suggestive, it was not clear that the improvement in survival was
reproducible or that Curosurf was responsible for the improved survival rates.
The purpose of this study was to investigate the role of Curosurf in improving lung function
and survival rates and reducing the complications of prematurity in very premature infants <
30 weeks gestational age at birth.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
